Apr 10

GEN: The Body’s Delta Force: Natural Killer Cells Re-Emerge

In a new feature published by GEN (Genetic Engineering & Biotechnology News), natural killer (NK) cells are in the spotlight showcasing their potential as the next generation of immunotherapies. This article explores how scientific and technological advances are helping cell therapy developers harness NK cells to expand the reach of cell therapy beyond oncology and into chronic and autoimmune conditions.

Artiva Biotherapeutics is recognized as being among the companies pioneering this approach. As GEN notes, Artiva focuses on leveraging NK cells’ innate safety, an ADCC-based mechanism, and scalable manufacturing to create off-the-shelf cell therapies that can be delivered in outpatient settings. Our AlloNK® platform is being evaluated in multiple clinical trials in autoimmune diseases.

Read the article in GEN here.

Recent Posts

See All

Pharmaceutical Manufacturer Q&A: Artiva Allogeneic NK Cell Therapies for Treating Autoimmune Disease

In this interview with Pharmaceutical Manufacturer, Artiva CEO Fred Aslan, M.D., discusses the unique advantages of natural killer (NK) cell therapies and the company’s mission to bring scalable, off-the-shelf treatments to patients with autoimmune diseases. The Q&A explores how Artiva’s AlloNK® platform—comprising non-genetically modified, cryopreserved NK cells combined with disease-targeting monoclonal antibodies—could offer a more...

GEN: The Body’s Delta Force: Natural Killer Cells Re-Emerge

In a new feature published by GEN (Genetic Engineering & Biotechnology News), natural killer (NK) cells are in the spotlight showcasing their potential as the next generation of immunotherapies. This article explores how scientific and technological advances are helping cell therapy developers harness NK cells to expand the reach of cell therapy beyond oncology and...

The Bio Report Podcast: Turning Natural Killers into Off-the-Shelf Therapies for Autoimmune Disease

NK cells, part of the innate immune system, serve as the body’s first line of defense. These cells can recognize and kill abnormal or infected cells. As therapies, they have the advantage over CAR-T and other cell therapies because they can be used off-the-shelf without undergoing gene editing or other genetic modifications. They also don’t...